



# News Release

## **Transfer of Business of Takeda Bio Development Center to its Parent Company --- Takeda's New Structure for Oncology Development Functions ---**

Osaka Japan, August 1, 2013 --- Takeda Pharmaceutical Company Limited ("Takeda") announced today its decision to transfer the current business of Takeda Bio Development Center Limited ("Takeda Bio") to Takeda under the agreement concluded between both parties. Dedicated oncology therapeutic area expertise will be maintained within Japan, with direct accountability to the Global Oncology Therapeutic Area Unit. The clinical development of Takeda's oncology products pipeline in Japan for which Takeda Bio has been responsible will be handled by Takeda's Pharmaceutical Development Division, and after the completion of the transfer scheduled in April 2014, Takeda Bio will be dissolved.

Takeda Bio has demonstrated track record of success including the regulatory approval in Japan of Vectibix® (generic name: panitumumab), a treatment for unresectable, advanced or recurrent colorectal cancer with wild-type KRAS, and also an NDA submission of brentuximab vedotin for the treatment of malignant lymphoma. Takeda Bio is currently conducting Phase 3 clinical trials of trebananib for ovarian cancer, orteronel for prostate cancer, and motesanib diphosphate for advanced non-squamous non-small cell lung cancer, among other trials. All the clinical trials will continue as currently planned under the responsibility and coordination of Takeda's Pharmaceutical Development Division.

With the transfer of the business of Takeda Bio, Takeda's development operations for both oncology and non-oncology pipelines in Japan will be fully integrated, supporting increased efficiencies and enhanced decision-making. These actions are part of Takeda's global initiatives to enhance its robust and efficient operating model.

Note: Takeda Bio with renewed name in April 2008 restarted as Takeda's wholly owned subsidiary, and prior to that, it had been wholly owned subsidiary of Amgen Inc. (Thousand Oaks, Calif.) in Japan. The launch of Takeda Bio was based on the agreement between Amgen Inc. and Takeda in February 2008, when both parties also agreed that Takeda licensed development pipeline from Amgen.

<Profile of Takeda Bio Development Center Limited>

- (1) Company name: Takeda Bio Development Center Limited
- (2) Location: Marunouchi Eiraku Building, 1-4-1, Marunouchi, Chiyoda-ku, Tokyo, Japan
- (3) Legal Representative: Haruo Kitado
- (4) Business: Development of pharmaceutical products
- (5) Established: March 26, 1992
- (6) Capital stock: 975 million yen
- (7) Shares: Non-listed
- (8) Shareholders of Takeda Bio: wholly owned subsidiary of Takeda Pharmaceutical Company Limited
- (9) Number of employees: 108 (as of July 1, 2013)